Webinar – Reduce Risk in VHH and BsAb Discovery with Early Immunogenicity Assessment Register Now Accelerating VHH and bispecific antibody development is no longer just about speed, it’s about progressing the right candidates with confidence. Early insights into safety, immunogenicity, and developability are critical to reducing costly downstream risks and delays. In this webinar, ProBio will showcase an integrated discovery strategy that combines single B-cell–based antibody discovery with advanced immunogenicity assessment. This approach enables rapid identification of high-quality candidates while providing early-stage insights to support smarter decision-making. Time Topic 14:00-14:50 A single B cell-based novel approach to accelerate the discovery of VHH and bispecific antibody Brief overview of current discovery strategy Introduction of a novel single B cell based discovery approach Case study with comparison between single B cell vs. phage display 14:50-15:20 De-risk of pre-clinical candidate by in silico and in vitro immunogenicity assessment The origin and impact of immunogenicity Current bottleneck of immunogenicity evaluation ProBio’s one-stop solution of immunogenicity assessment Speaker: Dr. Derek Chen, Sr. Director, Antibody Drug Discovery Dept., ProBio Related service: VHH Discovery BsAb discovery In vitro pharmacology Available materials « Previous Page ProBio Announces New Executive Appointments Next Page ProBio Accelerates Chimagen's Global Market Expansion, Paving the Way for Innovative Antibody Therapy » Contact us Phone: 1-877-436-7274 (Toll-Free); 1-732-885-9188 Fax: 1-732-210-0262
Latest WebinarsWebinar – Reduce Risk in VHH and BsAb Discovery with Early Immunogenicity AssessmentAccelerating In Vivo CAR-T Antibody Discovery and DevelopmentsdAb Discovery & ExpressCMC™ with Cell Line Development WebinarBiologics Webinar: From Lab Bench to GMP for BsAb & ADCFind More Therapeutic Antibody Categories